# Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)

> **NCT00442936** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1380 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Telcagepant potassium 150 mg
- **DRUG:** Telcagepant potassium 300 mg
- **DRUG:** Zolmitriptan 5 mg
- **DRUG:** Placebo to telcagepant 150 mg
- **DRUG:** Placebo to tecagepant 300 mg
- **DRUG:** Placebo to zolmitriptan 5 mg
- **DRUG:** Rescue medication

## Key facts

- **NCT ID:** NCT00442936
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-15
- **Primary completion:** 2007-10-02
- **Final completion:** 2007-10-02
- **Target enrollment:** 1380 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442936, "Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00442936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*